Comparison of the intraperitoneal and intravenous routes of cisplatin administration in an advanced ovarian cancer model of the rat.

A model of human advanced ovarian cancer was made by intra-abdominal inoculation of a cloned ovarian adenocarcinoma cell line of the Sprague-Dawley rat (ROT68/C1) into isologous newborn rats. Intra-abdominal tumors and tumors metastatic to the lung developed in 100% of the animals within 3 weeks after inoculation. With use of this model the intraperitoneal and intravenous routes of cisplatin (cis-diamminedichloroplatinum) administration were compared with regard to both the pharmacokinetics and the antitumor activity. After 2 hours of administration the serum cisplatin values were greater following use of the intraperitoneal route than with use of the intravenous route. Cisplatin values in the intra-abdominal tumor tissues were greater after the intraperitoneal route of administration than the intravenous route, and the growth was suppressed more prominently after intraperitoneal administration. No difference in drug values in the kidney tissues was found between the two administration routes. Thus the intraperitoneal route of cisplatin administration seems to be much more effective against advanced ovarian cancer confined to intra-abdominal cavity than does the intravenous route.